World News

The standards aim to establish consistent methods for assessing AI algorithms before hospitals and other healthcare providers introduce them into clinical practice.

The proposed restructuring will create two publicly traded companies, allowing each business to operate independently.

If completed, the transaction will add Emcitate to ANI’s portfolio, strengthening its position in the rare disease market.

Under the agreement, Boehringer will pay US$358million upfront for access to six biologic programmes, with Sino eligible for up to US$7billion in milestone payments and additional royalties on sales of any commercialised products.

The international research team found that natural killer (NK) cells in patients with mutations in the calreticulin (CALR) gene retain much of their ability to attack abnormal cells.

Hinova is also eligible to receive up to approximately US$1.07 billion in additional payments tied to development, regulatory and commercial milestones, as well as tiered royalties on net sales in markets outside Greater China.

The new site will expand AbbVie’s research capabilities and strengthen its presence in one of the UK’s established life sciences clusters.

The initiative marks a shift from earlier phases, which focused primarily on healthy volunteers, towards including people with a wider range of medical conditions.

Lumirix® is the first topical prescription treatment approved in Singapore that directly targets the disease’s pathophysiology, addressing an unmet need among patients with the condition.

The number of people requiring NTD interventions fell to 1.41 billion in 2024, representing a 36% decline from 2010 and a 19% reduction from 2020.